来源: MarketWatch ↗
This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month
|
暂时无法翻译，请重试。
来源报道重点
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.
在 MarketWatch 阅读原始报道 ↗